MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2024 International Congress

    Correlation Between Sleep and Quality of Life in People With Parkinson’s Disease Treated With Continuous Subcutaneous Infusion of Foslevodopa/Foscarbidopa

    I. Malaty, O. Vaou, R. Hauser, B. Bergmans, P. Odin, M. Shah, L. Bergmann, L. Harmer, R. Gupta, K. Chaudhuri (Gainesville, USA)

    Objective: To assess the correlation between sleep and quality of life (QoL) in people with Parkinson’s disease (PwP) receiving either oral levodopa/carbidopa immediate-release (LD/CD-IR) tablets…
  • 2024 International Congress

    Clinical and Safety Outcomes Using DBS Systems with Directionality and Multiple Independent Current Control – Real-World, USA Experience

    M. Okun, K. Foote, T. Zesiewicz, Y. Bezchlibnyk, A. Papanastassiou, O. Vaou, J. Carlson, J. Aldred, V. Krishna, C. Luca, J. Jagid, J. Durphy, L. Verhagen Metman, S. Sani, S. Ojemann, D. Kern, D. Weintraub, R. Ramdhani, A. Siadati, B. Sundaram, C. Zhao, D. Martinez, M. Siddiqui, S. Tatter, L. Chen, E. Goldberg (Gainesville, USA)

    Objective: Here, we present preliminary outcomes from an on-going, prospective, multicenter outcomes registry conducted in the USA consisting of patients implanted with directional Deep Brain…
  • 2024 International Congress

    The 201 Trial in Untreated Parkinson’s Disease

    M. Werner, CW. Olanow, A. Mcgarry, C. Meyer, E. Mancino, C. Klint, J. Pellecchia (Atlanta, USA)

    Objective: To evalute the safety, tolerability, clinical benefit and protein pathology status following risvodetinib (IkT-148009) treatment in participants with untreated Parkinson's disease. Background: RIsvodetinib is…
  • 2024 International Congress

    Long-term Safety and Efficacy for Motor Fluctuations and Quality of Life With Foslevodopa/Foscarbidopa in Patients With Advanced Parkinson’s Disease: Interim Results From an Ongoing Open Label Extension

    F. Bergquist, J. Aldred, C. Carroll, E. Danielsen, M. Facheris, R. Gupta, A. Jeong, A. Spiegel, V. Fung (Mölndal, Sweden)

    Objective: Evaluate long-term motor symptom control and improvement in quality of life (QoL) with foslevodopa/foscarbidopa (LDp/CDp) compared with baseline (BL) values from the parent study…
  • 2024 International Congress

    Parkinson’s Progression Markers Initiative (PPMI): Investigating Biomarker Driven PD Progression

    B. Mcmahon, A. Siderowf, T. Simuni, C. Tanner, B. Mollenhauer, C. Coffey, D. Galasko, K. Poston, L. Chahine, R. Dobkin, T. Foroud, K. Kieburtz, D. Weintraub, K. Merchant, M. Frasier, T. Sherer, S. Chowdury, E. Brown, R. Alcalay, A. Videnovic, K. Fabrizio, E. Flagg, C. Stanley, K. Marek (Baltimore, USA)

    Objective: PPMI is a longitudinal, observational study enrolling PD participants, individuals at risk for PD, and healthy controls (HCs). The study investigates clinical, imaging, genetic…
  • 2024 International Congress

    Clinic vs Self-Referral for a Home-Based Fracture Prevention Trial of Zoledronate vs Placebo in Patients with Neurodegenerative Parkinsonism

    C. Tanner, N. Luthra, S. Goldman, R. Zuzuarregui, E. Brown, C. Meng, J. Perkins, T. Hue, C. Schambach, D. Kreisel, D. Young, I. Bledsoe, L. Racelo, P. Nanda Kumar, P. Ranola, M. Schwarzschild, R. Dorsey, A. Espay, S. Krischer, J. Falcon, C. Comella, M. Siddiqui, F. Gao, M. Ledoux, E. Byrd, I. Litvan, N. Mcfarland, K. Mitchell, D. Standaert, J. Beck, K. Williams, M. Drake, D. Bauer, K. Lyles, S. Cummings (SAN FRANCISCO, USA)

    Objective: To evaluate recruitment, eligibility and characteristics of clinic referred vs self-referred patients in the ongoing Trial of Parkinson’s and Zoledronate (TOPAZ, NCT03924414) Background: People…
  • 2024 International Congress

    Therapeutic restoration of Faecalibacterium prausnitzii in Parkinson’s disease using targeted fructoligosaccharides: a double-blind, placebo-controlled, cross-over trial

    J. O'Sullivan, N. Jayabalan, N. Birch, D. Mondhe, A. Lehn, R. Gordon, R. Adan (Brisbane, Australia)

    Objective: In this study, we evaluated the effect of targeted fructoligosaccharide (FOS) therapy to restore the beneficial butyrate producer Faecalibacterium prausnitzii, one the most highly reduced…
  • 2024 International Congress

    Loganic Acid Alleviates the Bidirectional Olfactory-Brain NLRP3 Inflammasome Activation and Rescues Dopaminergic Neurons in Experimental Models of Parkinson’s Disease

    S. Panda, P. Panja, V. Naidu (Guwahati, India)

    Objective: The study aimed to delineate the molecular mechanism involved in bidirectional olfactory-brain dysfunction through the NLRP3 inflammasome signaling activation in in-vitro and in-vivo model…
  • 2024 International Congress

    Evaluation of neuroprotective effects of doxycycline in a primate model of PD

    L. Pedrosa, L. Leal, J. Muniz, E. Del-Bel, B. Gomes, L. Krejcová (Belém, Brazil)

    Objective: To evaluate the effects of doxycycline on the outcomes of 6-OHDA-induced Parkinson's disease in Sapajus apella monkeys. Background: Doxycycline (doxy) has been reported as…
  • 2024 International Congress

    If Oral Levodopa is not Possible, Keep Calm and Breathe Deeply

    D. García-Meléndez, E. Gisbert Tijeras, B. Carmona Moreno, E. Botia Paniagua (Alcázar San Juan, Spain)

    Objective: Include inhaled levodopa as a therapeutic option in those patients who, due to post-surgical problems, cannot use oral treatments. Background: The development of motor…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Effect of Ketone Ester Supplementation on Motor and Non-Motor symptoms in Parkinson's Disease
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Welcome to the MDS Abstracts Site
    • Effect of marijuana on Essential Tremor: A case report
    • Advanced Search
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley